Joint Formulary & PAD

Ibandronic acid - Osteoporosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

150mg tablets 
(note - 50mg tablets are not licensed for this indication)

 

Status 2

Red
Formulations :
  • Intravenous infusion
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Ibandronic acid
Indication :
Osteoporosis
Group Name :
Keywords :
Brand Names Include :
Bonviva
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4
Traffic Light Entries :
2

Other Indications

Below are listed other indications that Ibandronic acid is used to treat.

Committee Recommendations (1)

GENERIC Ibandronic acid tablets 150mg have been considered by the PCN and have been assigned a GREEN traffic light status.
However, Alendronate and risedronate weekly preparations are recommended as the most cost-effective, 1st line treatment options. Ibandronic acid remains an alternative option but is not included within the local guidelines below

NOTE - the branded product, Bonviva, was considered BLACK at the PCN in May 2017.